| Name | Title | Contact Details |
|---|
Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.
Flare Capital Partners invests and specializes exclusively in the healthcare technology sector. Working side-by-side, Flare Capital parlays strengths in business and medicine into action that supports entrepreneurs who provide innovative solutions and strive to be market leaders.
IncludeHealth is a digital health and performance company delivering next-generation musculoskeletal care and training. Offered through a monthly subscription, their platform provides a comprehensive digital suite that pairs HIPAA compliant cloud software with connected equipment, sensors and data to quantify and qualify human performance. This unique pairing provides breakthrough capabilities such as centralized and standardized protocols, outcomes-based data collection, autonomous instruction and documentation, and location agnostic delivery to produce better outcomes with lower costs. The proprietary technology at IncludeHealth has been recognized with 28 international innovation and health awards and is utilized in orthopedics, neuroscience, pediatric care, senior care, government, and general wellness facilities.
Educational Concepts in Medicine is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Intrigma is a leader in medical scheduling solutions that deliver bottom-line impact to medical groups, hospitals and hospital systems.